Sugi Predict

Sugi Predict / Compounds / SCHEMBL2194632

SCHEMBL2194632

SCHEMBL2194632

COC(=O)[C@H](C)OS(C)(=O)=O

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CA14 Q9ULX7 4/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ CA12 O43570 4/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CA9 Q16790 2/20 0.35
▸ CA7 P43166 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ KMT2A Q03164 4/20 0.33
▸ MEN1 O00255 3/20 0.33
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ MME P08473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1874521 1.00 CA14 (0.46) CA14ALDH1A1CA12SMN1; SMN2CA9
SCHEMBL1874519 1.00 CA14 (0.46) CA14ALDH1A1CA12SMN1; SMN2CA9
SCHEMBL9590813 0.83 ALDH1A1 (0.48) CA14ALDH1A1CA12USP2TSHR
SCHEMBL29471321 0.82 CA14 (0.34) CA14ALDH1A1CA12
SCHEMBL17469827 0.81 CA14 (0.46) CA14ALDH1A1CA12SMN1; SMN2CA9
SCHEMBL6907573 0.79 CA14 (0.45) CA14CA12SMN1; SMN2CA9CA7
SCHEMBL28948443 0.79 ALDH1A1 (0.50) CA14ALDH1A1CA12CA9TSHR
SCHEMBL6907571 0.79 CA14 (0.45) CA14CA12SMN1; SMN2CA9CA7
SCHEMBL22292064 0.79 CA14 (0.45) CA14CA12SMN1; SMN2CA9CA7
SCHEMBL6910511 0.79 CA14 (0.45) CA14CA12SMN1; SMN2CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100467452-C Method for preparing haloxyfop-P-methyl with high optic purity UNIV ZHEJIANG TECHNOLOGY (CN) 2009-03-11 — — CN claimed
CN-1944409-A Method for preparing haloxyfop-P-methyl with high optic purity UNIV ZHEJIANG POLYTECHNIC (CN) 2007-04-11 — — CN claimed
EP-1671939-A1 Process for preparing enantiomerically enriched esters of 2-fluorocarboxylic acids Lanxess Deutschland GmbH (DE) 2006-06-21 — — EP claimed
WO-2024220399-A1 PYRAZOLOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2024-10-24 — — WO disclosed
CN-117567364-A Process for optimally producing high-efficiency haloxyfop-R-methyl 吴忠领航生物药业科技有限公司 2024-02-20 — — CN disclosed
CN-116888094-A Method for preparing D-alanine alkyl ester, derivative thereof, and pharmaceutical or agricultural product comprising same 株式会社LG化学 2023-10-13 — — CN disclosed
CN-116535351-A Method for synthesizing efficient gaicao energy 江苏瑞恒新材料科技有限公司 2023-08-04 — — CN disclosed
CN-116171269-A Process for preparing D-alanine alkyl ester 株式会社LG化学 2023-05-26 — — CN disclosed
WO-2023055050-A1 METHOD FOR PREPARING HIGHLY PURE N-ACYL DERIVATIVE 주식회사 팜한농 2023-04-06 — — WO disclosed
WO-2023277590-A1 METHOD FOR PREPARING ALKYL-D-ALANINATE, ALKYL-D-ALANINATE, ALKYL-D-ALANINATE DERIVATIVE, AND PHARMACEUTICAL OR AGRICULTURAL PRODUCT INCLUDING SAME 주식회사 엘지화학 2023-01-05 — — WO disclosed
US-20220354860-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF FOCHON PHARMACEUTICALS, LTD. (CN) 2022-11-10 — — US disclosed
US-20050277670-A1 Chemokine receptor binding compounds ANORMED INC. 2005-12-15 — — US disclosed
WO-2005059107-A2 CHEMOKINE RECEPTOR BINDING COMPOUNDS ANORMED INC. (CA) 2005-06-30 — — WO disclosed
EP-1155616-B1 Process for the preparation of (N-phenylacetyl-N-2,6-xylil)methyl alaninate ISAGRO SPA (IT) 2003-01-29 — — EP disclosed
EP-0946093-B1 FUNGICIDAL COMPOSITIONS BASED ON (N-PHENYLACETYL-N-2,6-XYLYL)METHYL ALANINATE ISAGRO SPA (IT) 2002-08-28 — — EP disclosed
EP-1155616-A1 Process for the preparation of (N-phenylacetyl-N-2,6-xylil)methyl alaninate ISAGRO S.p.A. (IT) 2001-11-21 — — EP disclosed
US-6228885-B1 Fungicidal compositions based on (N-phenylacetyl-N-2,6-XYLYL)methyl alaninate ISAGRO S.P.A. (IT) 2001-05-08 — — US disclosed
WO-2000076960-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE N-ACYL DERIVATIVES OF METHYL N-(2,6-DIMETHYLPHENYL)-D-ALANINATE ISAGRO S.P.A. (IT) 2000-12-21 — — WO disclosed
EP-0946093-A2 FUNGICIDAL COMPOSITIONS BASED ON (N-PHENYLACETYL-N-2,6-XYLYL)METHYL ALANINATE ISAGRO S.p.A. (IT) 1999-10-06 — — EP disclosed
WO-1998026654-A2 FUNGICIDAL COMPOSITIONS BASED ON (N-PHENYLACETYL-N-2,6-XYLYL)METHYL ALANINATE ISAGRO S.P.A. (IT) 1998-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220354860-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF NUDT1, UGP2, NUDT21 CA14 3611/4885ALDH1A1 221/4885CA12 3465/4885
US-20050277670-A1 Chemokine receptor binding compounds CCR5, CXCR3, CCL5 CA14 4038/4885ALDH1A1 3358/4885CA12 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.